Shorts

Why Use Frontline Bispecifics in Myeloma
0:33
Why Use Frontline Bispecifics in Myeloma
a year ago
by
Marc Raab, MD
Why "One Size" Policies Fail Rural Communities
0:33
Why "One Size" Policies Fail Rural Communities
a year ago
by
Enrique Soto Pérez de Celis, MD, MSc
Shifting Health Care Culture Requires Everyone Learning Together
0:35
Shifting Health Care Culture Requires Everyone Learning Together
a year ago
by
Cheyenne Corbett
Why Cancer Care Needs a "Both/And" Approach
0:35
Why Cancer Care Needs a "Both/And" Approach
a year ago
by
Cheyenne Corbett
Ego vs the Patient: The Hardest Medical Decision
0:32
Ego vs the Patient: The Hardest Medical Decision
a year ago
by
Cheyenne Corbett
Why Oncology is a "Black Box" for Most Primary Care Providers
0:26
Why Oncology is a "Black Box" for Most Primary Care Providers
a year ago
by
Cheyenne Corbett
The Silent Crisis in Rural Health Care
0:37
The Silent Crisis in Rural Health Care
a year ago
by
Enrique Soto Pérez de Celis, MD, MSc
Can Quality Cancer Care Reach Rural America?
0:38
Can Quality Cancer Care Reach Rural America?
a year ago
by
Enrique Soto Pérez de Celis, MD, MSc
The Biggest Challenges Facing Rural Cancer Care
0:41
The Biggest Challenges Facing Rural Cancer Care
a year ago
by
Enrique Soto Pérez de Celis, MD, MSc
The Power of Perseverance: Finding Strength in Shared Journeys
1:01
The Power of Perseverance: Finding Strength in Shared Journeys
a year ago
by
Jered Haddad
Empowering Conversations: A Guide for Supporting New Diagnoses
0:38
Empowering Conversations: A Guide for Supporting New Diagnoses
a year ago
by
Jered Haddad
The Best Advice From an Oncologist to a Patient
0:48
The Best Advice From an Oncologist to a Patient
a year ago
by
Michael Cole
Unlocking New Possibilities in Bladder Cancer Treatment
0:41
Unlocking New Possibilities in Bladder Cancer Treatment
a year ago
by
Andrea Necchi, MD
Dr Patel: Considerations for Adjuvant Cemiplimab in CSCC
1:23
Dr Patel: Considerations for Adjuvant Cemiplimab in CSCC
a year ago
by
Vishal A. Patel, MD
Trial Opens Up More Avenues for Treatment in Patients with Bladder Cancer
1:10
Trial Opens Up More Avenues for Treatment in Patients with Bladder Cancer
a year ago
by
Christof Vulsteke, MD, PhD
A 13-Year-Old Drug’s Persisting Power in Prostate Cancer
0:41
A 13-Year-Old Drug’s Persisting Power in Prostate Cancer
a year ago
by
Stephen J. Freedland, MD
Clinical Trial Achieves 60% Reduction in the Risk of Tumor Recurrence
1:16
Clinical Trial Achieves 60% Reduction in the Risk of Tumor Recurrence
a year ago
by
Christof Vulsteke, MD, PhD
Pembrolizumab and Enfortumab Vedotin Demonstrate Potential in Bladder Cancer Treatment
1:22
Pembrolizumab and Enfortumab Vedotin Demonstrate Potential in Bladder Cancer Treatment
a year ago
by
Christof Vulsteke, MD, PhD
Delaying Progression in Nonmetastatic Prostate Cancer: Insights from EMBARK
0:36
Delaying Progression in Nonmetastatic Prostate Cancer: Insights from EMBARK
a year ago
by
Stephen J. Freedland, MD
Perioperative Pembrolizumab Doubles Survival in Metastatic Bladder Cancer
1:11
Perioperative Pembrolizumab Doubles Survival in Metastatic Bladder Cancer
a year ago
by
Christof Vulsteke, MD, PhD
The Challenge of Treating High-Risk nmCSPC
0:29
The Challenge of Treating High-Risk nmCSPC
a year ago
by
Stephen J. Freedland, MD
Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer
0:35
Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer
a year ago
by
Bradley J. Monk, MD
Adverse Events to Watch for With Ribociclib
0:30
Adverse Events to Watch for With Ribociclib
a year ago
by
Sara A. Hurvitz, MD
Dr Mayer Discusses PFS Data From evERA at ESMO 2025
0:45
Dr Mayer Discusses PFS Data From evERA at ESMO 2025
a year ago
by
Erika Mayer, MD, MPH
How a New Drug is Changing Breast Cancer Treatment Forever
0:19
How a New Drug is Changing Breast Cancer Treatment Forever
a year ago
by
Joyce A. O’Shaughnessy, MD
1 in 3 Breast Cancer Patients at High Risk
0:21
1 in 3 Breast Cancer Patients at High Risk
a year ago
by
Joyce A. O’Shaughnessy, MD
Why Understanding Tumor Biology is Key to Better Breast Cancer Care
0:37
Why Understanding Tumor Biology is Key to Better Breast Cancer Care
a year ago
by
Sarah Premji, MD
FDA Requires 5 Years of Follow Up—Is It Too Much?
0:37
FDA Requires 5 Years of Follow Up—Is It Too Much?
a year ago
by
Harpreet Singh, MD
How Breast Cancer Treatment Became More Personalized & Effective
0:20
How Breast Cancer Treatment Became More Personalized & Effective
a year ago
by
Sarah Premji, MD
Reviewing the FDA Draft Guidance on Radiopharmaceuticals
0:17
Reviewing the FDA Draft Guidance on Radiopharmaceuticals
a year ago
by
Harpreet Singh, MD